ABSTRACT
Ten years ago the cloning of two inter. IL.1 was one of the first cytokines described.
Before being so named, IL-i was studied for many years for its ability to cause fever, stimulate ProIL-la present on the surface of several cells is biologically active.
Approximately 10-15% of the IL-la is myristoylated (41). It is believed that this form is transported to the cell surface where it is called membrane IL-i (42) (Fig. i) . The IL-1f3 propiece is also myristoylated, but unlike IL-ia, prolL-i(3 has no membrane form and is only marginally active. Some IL-if3 is found in lysosomes (43) or associated with microtubules (44), and either localization may play a role in the secretion of
After synthesis, prolL-if3 also remains primarily cytosolic until it is cleaved and transported out of the cell. In mononuclear phagocytes, a small amount of prolL-ifi is secreted from intact cells. Although the pathway for this secretion remains unknown, release of prolL-113 appears to be an event separate from secretion of the mature molecule.
Unlike the prolL-la, prolL-113 requires cleavage for optimal secretion and biological activity. An intracellular cysteine protease is highly specific for cleaving prolL-ifi at the aspartic acid-alanine (amino acids 116-117) position (45, 46) ( The cDNA encoding ICE has been cloned (45, 46) and the tertiary structure of its active site has been described (47). ICE does not cleave the IL-la precursor.
Other enzymes have been found that do cleave the IL-ia precursor but these seem less specific than ICE.
In the presence of a tetrapeptide substrate inhibitor of ICE, the secretion of mature IL-ifi is inhibited and prolL-ifi accumulates outside the cell (45). This finding supports the concept that prolL-ifi can be released from the cell independent of processing by ICE (Fig. 1 In genes-al, IL-ia has a higher affinity for IL-1RI whereas IL-113 has a higher affinity for IL-iRil (73). may also phosphorylate an upstream kinase (? p97 kinase), which in turn phosphorylates stress-associated mitogen-activated protein (MAP) kinases p38 and p54a kinases. These stress-associated MPA kinases, in turn, phosphorylate serine and threonine on proteins such as the IL-IR itself and specifically threonine 669 on the epidermal growth factor receptor (EGFR). These stress-associated kinases activate other kinases including a p50 kinase that phosphorylates heat shock protein 27 (hsp27). The p50 kinase is probably MAP kinase-activated protein kinase-2 (MAPKAP kinase-2). Another kinase that becomes phosphorylated is Ji-casein kinase. A substrate for these kinases may be PLAP, which leads to prostaglandin E2 (PGE2) synthesis from AA by constitutive cyclooxygenase.
Of importance is the finding that
Another pathway that may contribute to phosphorylation of protein kinases is activation of a nonphosphatidylinositol phospholipase C (PLC). This pathway results in the rapid hydrolysis of phosphatidylcholine (PC), phosphatidylethanoloamine (FE) or phosphatidylserine (PS). A product of these hydrolyses generates diacylglycerol (DAG), which activates protein kinase C (PKC) or other kinases. IL-i binding to the receptor has been reported to trigger GTP-hydrolysis leading to increased adenyl cyclase, cAMP an infection or antigen challenge, whereas the latter products are needed by the host to mount a successful defense, including an inflammatory response.
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The FASEB Journal However, a systemic injection of either IL-la or IL-113 into animals or humans mimics systemic inflammation; fever, chills, myalgias, joint aches, headache, neutrophilia, and circulating cytokines are induced (1 i3). At higher doses of IL-i, hypotension and a capillary leak syndrome are observed and require supportive therapy (114). Local injections of IL-i into animal joints mimic changes characteristic of acute and chronic joint diseases.
Levels of IL-i13 in the circulation of animals or humans correlate with severity of some diseases (115).
Yet an increased production of IL-ia or IL-lb in association with disease is not sufficient to implicate the cytokmne as causative in the pathogenesis of any particular disease or biological process. Convincing data that IL-i has a causative role in disease or in the response to external stress have been reported using IL-iRa, IL-isRi, neutralizing anti-IL-i antibodies, antibodies to the IL-iRI, or antisense oligonucleotides to IL-1RI (reviewed in refs ii, 116)). In general, these antagonists have been administered just before the injection of a lethal amount of bacteria or the initiation of an inflammatory process (i 17). Although these antagonists block endogenous IL-i activity, they are given before a significant amount of IL-i is synthesized. As such, their use does not inform us whether the amount of endogenous IL-i antagonists produced during disease affects outcome.
In fact, endogenous levels of IL-iRa can be high and during infection are usually present in 100-. fold molar excess over those of IL-i13 (118, 119). Endogenous IL-iRa production may be an important disease outcome because neutralizing antibodies to endogenous IL-iRa worsens disease (120, 121).
INTRINSIC LIMITS ON IL-i PRODUCTION AND ACTIVITY
During the past 10 years, several characteristics of the biology of IL-i have been uncovered that appear to limit its production and activity. In colloquial terms, there are several natural roadblocks for IL-i and each is highly specific.
For example, no other cytokine has its own natural antagonist with a high affinity for the signaling receptor.
Of the two IL-i agonists, reducing the production and activity of IL-i13 are the most striking.
Starting with gene expression, IL-ia mRNA is readily translated into IL-la protein.
On the other hand, most of the IL-l13 mRNA is not translated but requires a second signal for translation.
ProIL-ia is active whereas prolL-i13 requires cleavage to its mature form.
However 
